Advanced Key Initiatives for NDA Submission Launched Non-Branded Metabolic Acidosis Disease Awareness Campaign Presented TRCA-301 Pivotal Trial Results at ASN Kidney Week Late-Breaker Session Webcast Today at 5:00 pm ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 8, 2018-- Tricida, Inc.

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 1, 2018-- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its third quarter 2018 financial results after the close of market on Thursday, November 8, 2018 . Tricida will host a conference call and webcast at 5:00 pm Eastern Time

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 4, 2018-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-dosed polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD),

Completed Positive Pivotal Phase 3 Trial for TRC101 Completed $255.6 Million Initial Public Offering Webcast Today at 5:00 pm ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 8, 2018-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 1, 2018-- Tricida, Inc. (Nasdaq: TCDA) today announced the hiring of Dawn Parsell , Ph.D., as Senior Vice President of Clinical Development. Dr. Parsell will lead Tricida’s clinical development of TRC101 as the company prepares to begin its

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 31, 2018-- Tricida, Inc. (NASDAQ: TCDA) today announced that it will report its second quarter 2018 financial results after the close of market on Wednesday, August 8, 2018 . Tricida will host a conference call and webcast at 5:00 pm Eastern Time

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 2, 2018-- Tricida, Inc. (NASDAQ: TCDA), a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-dosed polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease,

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Tricida, Inc., a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-dosed polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease, today announced the pricing of

SOUTH SAN FRANCISCO, Calif., June 5, 2018, (Business Wire) Tricida, Inc., a late-stage pharmaceutical company, announced results from its pivotal Phase 3 double-blind, randomized, placebo-controlled, multi-center Phase 3 clinical trial, TRCA-301, in 217 chronic kidney disease (CKD) patients with

SOUTH SAN FRANCISCO, Calif., June 4, 2018, (Business Wire) Tricida, Inc. announced today that Kathryn Falberg has joined its Board of Directors and has been named the chairperson of its Audit Committee. Ms. Falberg is a seasoned pharmaceutical industry executive with extensive leadership and